Navigation Links
Growth hormone analog may reduce risk of fatty liver disease in HIV-infected patients
Date:7/19/2014

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. Patients infected with HIV demonstrate a high prevalence of nonalcoholic fatty liver disease, estimated at 30 percent to 40 percent. The issue is being released early to coincide with the International AIDS Conference.

In human immunodeficiency virus (HIV) infection, abdominal fat accumulation is associated with ectopic (out of place) fat accumulation in the liver. Nonalcoholic fatty liver disease (NAFLD) may progress to end-stage liver disease and liver cancer. To date, there are no approved pharmacologic strategies to reduce liver fat. Tesamorelin specifically targets abdominal fat reduction but its effects on liver fat are unknown, according to background information in the article.

Takara L. Stanley, M.D., of Massachusetts General Hospital and Harvard Medical School, Boston, and colleagues randomly assigned 50 antiretroviral-treated HIV-infected men and women with abdominal fat accumulation to receive tesamorelin (n=28), or placebo (n=22), subcutaneously daily for 6 months.

The researchers found a modest but statistically significant decrease in liver fat with tesamorelin. Hepatic lipid to water percentage (a measure of liver fat), decreased in the tesamorelin group (median, -2.0 percent) compared with placebo (median, 0.9 percent). In addition, there was a significant reduction in abdominal fat: the average change was -9.9 percent with tesamorelin vs 6.6 percent with placebo.

"The decrease in liver fat in this study suggests that strategies to reduce visceral adiposity merit further investigation in HIV-infected patients with NAFLD, a condition for which there are no approved treatments. Importantly, NAFLD is associated with visceral adiposity and other metabolic abnormalities in HIV," the authors write.

"Further studies are needed to determine the clinical importance and long-term consequences of these findings."


'/>"/>

Contact: Cassandra Aviles
cmaviles@partners.org
617-724-6433
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
2. Low oxygen levels could drive cancer growth
3. Report using private health claims data shows prices are driving health spending growth
4. Mutations impair childhood growth and development by disrupting organization of chromosome pairs
5. Disease that stunts infants growth traced to same gene that makes kids grow too fast
6. Scientists discover mechanism that promotes lung cancer growth and survival
7. Nerve growth factors elevated in pancreatic cancer model
8. Exercise Wont Affect Breast Milk, Babys Growth: Study
9. QTrade's New Facility Anticipates Dramatic Growth of Tea Industry
10. Rising Solar Engineering and Design Firm Enters 1.7 MW's in Connecticut ZREC Auction and Positions for Future Growth
11. Mahvrick Expands to Brazil, Russia, India, China to Support Existing Client Customer Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... , ... Bill Howe started his sewer and drain company in 1980 focusing ... the team, the Bill Howe brand was born and they began cultivating their mission ... to the San Diego community in which they worked, lived and were raising their ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the ... of a moisturizer with the power of an anti-aging concentrate. , ...
(Date:4/27/2017)... PHILADELPHIA and DENVER (PRWEB) , ... April 27, ... ... Jewish Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an ... Institute is enabled by the continuing support of the Jane and Leonard Korman ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... the 2017 North American CAREGiverSM of the Year for her extraordinary compassion and ... of its 60,000 North American professional caregivers for the prestigious award each year ...
(Date:4/27/2017)... Rosa, CA (PRWEB) , ... April 27, 2017 , ... ... Canales, MD , have been asked to present at the upcoming Aesthetic Meeting. Held ... from April 27-May 2. Drs. Furnas and Canales will lend their expertise to the ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets ... Pipeline and Market Prospects: Addressing Production Complexities Through Risk ... offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities ... in-depth assessment of the current trends in the global ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: